Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells
- 1 January 2016
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 370 (2) , 332-344
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation of China (81372471, 81171491, 81472865, 81473504)
- Liaoning Natural Science Foundation (201102056)
This publication has 49 references indexed in Scilit:
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM ExpressionCancer Research, 2011
- Four faces of cellular senescenceJournal of Cell Biology, 2011
- PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomasPigment Cell & Melanoma Research, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomasMolecular Cancer Therapeutics, 2009
- Autophagy mediates the mitotic senescence transitionGenes & Development, 2009
- Role of autophagy in cancerNature Reviews Cancer, 2007